LAXAI Life Sciences, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced the appointment of Dr. Sripathy Venkatraman, PhD, MBA, as its new Chief Executive Officer.
Dr. Venkatraman brings over 25 years of experience in small molecule and biologics drug development, manufacturing, and strategic growth. He most recently served as Head of Global R&D at Curia, where he led large-scale scientific operations, expanded global capabilities, and built high-performance teams. Joining Curia (formerly AMRI) in 2002, he progressed through scientific and leadership roles, ultimately overseeing the R&D business unit.
“As our new CEO, Sri not only brings deep scientific and operational expertise, but also a clear strategic vision for LAXAI’s evolution into a global CRDMO partner,” said Vamsi Maddipatla, Chairman of LAXAI Life Sciences. “His experience in scaling complex operations, building high-performance teams, and driving innovation across modalities makes him uniquely qualified to lead LAXAI through its next phase of growth.”
At Curia, Dr. Venkatraman played a pivotal role in strategic transformations, including navigating founder-led and private equity transitions. He was instrumental in expanding capabilities in small molecules and emerging therapeutic platforms, integrating global teams, and building scalable platforms that strengthened partnerships with biotech and pharmaceutical companies.
“LAXAI’s reputation for scientific excellence, its strong foundation, and the opportunity to shape and grow a differentiated global business is what drew me to this opportunity,” said Dr. Venkatraman. “I’m excited to build on this momentum, expand our global footprint, and invest in capabilities that matter to biotech innovators. Our goal is to become the CRDMO of choice, not just a vendor, but a true scientific partner.”
